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Abstract—Many effects believed to be because of angiotensin II (Ang II) are attributable to the action of endothelin (ET)-1, 
which is released/produced by Ang II. We investigated whether Ang II elicits its positive inotropic effect (PIE) by the 
action of endogenous ET-1, in addition to the role played by reactive oxygen species (ROS) in this mechanism. Cat 
cardiomyocytes were used for: (1) sarcomere shortening measurements; (2) ROS measurements by epifluorescence; (3) 
immunohistochemical staining for preproET-1, BigET-1, and ET-1; and (4) measurement of preproET-1 mRNA by 
RT-PCR. Cells were exposed to 1 nmol/L Ang II for 15 minutes. This low concentration of Ang II increases sarcomere 
shortening by 29.2^3.7% (P^0.05). This PIE was abrogated by Na^/H^ exchanger or Na^/Ca2^ exchanger reverse 
mode inhibition. The production of ROS increased in response to Ang II treatment (^ROS respect to control: 68^15 
fluorescence units; P^0.05). The Ang II–induced PIE and ROS production were blocked by the Ang II type 1 receptor 
blocker losartan, the nonselective ET-1 receptor blocker TAK044, the selective ETA receptor blocker BQ-123, or the 
ROS scavenger N-(2-mercapto-propionyl)glycine. Exogenous ET-1 (0.4 nmol/L) induced a similar PIE and increase in 
ROS production to those caused by Ang II. Immunostaining for preproET-1, BigET-1, and ET-1 was positive 
in cardiomyocytes. The preproET-1 mRNA abundance increased from 100^4.6% in control to 241.9^39.9% in 
Ang II–treated cells (P^0.05). We conclude that the PIE after exposure to 1 nmol/L Ang II is due to endogenous ET-1 
acting through the ETA receptor and triggering ROS production, Na^/H^ exchanger stimulation, and Na^/Ca2^ 
exchanger reverse mode activation. (Hypertension. 2006;47:727-734.)
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There is a large amount of evidence to demonstrate that several effects believed to be attributed to angiotensin II 
(Ang II) are caused by the release/production of endothelin 
(ET) from different cells. Ito et al1 reported Ang II–induced 
hypertrophy in neonatal rat cardiomyocytes via the release/ 
production of ET-1. The resulting hypertrophy was prevented 
by blocking ETA receptors or by using antisense oligonucle­
otides directed against preproET mRNA.1 In addition, Liang 
and Gardner,2 also working with rat neonatal myocytes, 
reported that the increase in brain natriuretic peptide (BNP) 
gene promoter activity induced by Ang II was prevented by 
blocking ETA receptors. Furthermore, in vivo studies have 
also shown that several effects of Ang II can be attenuated 
or abolished by blocking ET receptors.3,4 These findings 
strongly suggest that Ang II induces the release/production of 
ET-1 from cells which, acting in an autocrine fashion on ET 
receptors, trigger intracellular signals.
Ang II is a classical stimulus for NADPH oxidase and 
superoxide production,5–7 and a role for this intracellular signal­
ing pathway has been proposed to explain several physiological 
effects of this peptide.5,8 Alternatively, the stimulation of 
NADPH oxidase by ET-19,10 and the involvement of this 
mechanism in determining some of its physiological effects11 
have also been reported. The aim of the present study, which was 
performed in isolated adult cat ventricular myocytes was to 
determine: (1) whether the release/production of ET-1 by Ang II 
could be detected in adult cardiomyocytes, (2) its implications in 
cardiac contractility, and (3) the role played by reactive oxygen 
species (ROS) in this mechanism.
Methods
The investigation conforms to the Guide for the Care and Use of 
Laboratory Animals published by the National Institutes of Health 
(Publication No. 85-23, revised 1996).
Myocytes Isolation
Cat ventricular myocytes were isolated according to the technique 
described previously.12
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Sarcomere Shortening
To measure sarcomere length (SL), myocytes were placed in a 
perfusion chamber on the stage of an inverted microscope (Nikon) 
and continuously superfused with a solution containing (mM) 5 KCl, 
118 NaCl, 1.2 MgSO4, 0.8 MgCl2, 1.35 CaCl2, 10 glucose, and 20 
NaHCO3 (pH 7.4) after continuous bubbling with 5% CO2 and 95% 
O2. The myocytes were stimulated via 2-platinum electrodes on 
either side of the bath at 0.5 Hz. The SL was recorded by a specific 
software (Ion Wizard). The myocytes were observed using a video 
camera connected to the microscope. The SL was measured in a 
determined region of the myocyte. The software estimated the most 
frequent SL in that region using fast Fourier transform analysis (Ion 
Optix). The SL was measured at 30°C (TC2, Cell micro controls).
RNA Measurements by RT-PCR
Total RNA was isolated from the cardiomyocytes suspension using 
the RNeasy kit (Qiagen) according to the manufacturer's instruc­
tions. RNA (0.8 ^g) was reverse-transcribed using the Omniscript 
RT kit (Qiagen). A dilution of the resulting cDNA was used to 
quantify the relative content of mRNA by real-time PCR (iCycler iQ 
Real-Time PCR Detection System, Bio-Rad) using appropriate 
primers and SYBR Green as fluorescent probe.13 The following 
primers designed using Primer3 software were used: GAPDH: for­
ward primer 5^-GGGTGTGAACCACGAGAAAT-3^; reverse 
primer 5^-CCACAGTCTTCTGAGTGGCA-3^; preproET-1: for­
ward primer 5^-CAGACAAAGAACTCCGAGCC-3^; reverse 
primer 5^-GGTCTTGATGCTGTTGCTGA-3^; preproET-3: forward 
primer 5^-TCTCCACAGACACGCTTACG-3^; reverse primer 5^- 
TGACTTCAGCCTTTGACGTG-3^; and ET converting enzyme 1 
(ECE-1): forward primer 5^-ACAAGCTCCTTTCTCGACCA-3^; 
3^-GCCCAGGTTGTTTTCTGTGT-5^. PCR reactions were per­
formed with TaqDNA polymerase (Invitrogen). Fluorescence data 
were acquired at the end of extension. A melt analysis was run for all 
of the products to determine the specificity of the amplification. The 
cycle threshold values for each gene were measured and calculated 
by computer software (iCycler IQ OSS, version 3.0a, Bio-Rad). The
Figure 1. Effect of Ang II on SL shorten­
ing of cardiac isolated myocytes. (A) 
Continuous recording of a myocyte SL 
shortening before and after the addition 
of 1 nmol/L Ang II, which induced an 
increase in contractility of ^30%. (B) 
Individual traces corresponding with “a” 
and “b” of A. (C) average changes in SL 
shortening (n^11), expressed as ^%of 
initial length (Lo). (D) Dose-response 
curve for different concentrations of Ang 
II, from 1 to 500 nmol/L, in the absence 
or presence of TAK044 (1 ^mol/L). The 
maximal PIE was obtained with 100 
nmol/L Ang II. TAK044 shifted the dose­
response curve to the right and com­
pletely blocked the inotropic effect of 1 
nmol/L Ang II indicating that this effect 
was entirely caused by the action of the 
endogenous ET released/produced by 
Ang II. However, the data show that 
concentrations ^1 nmol/L are activating 
other mechanisms than the autocrine 
signal triggered by Ang II. *P^0.05 vs 
control.
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cycle threshold values for each gene were normalized by those 
GAPDH in the same sample. The primers for preproET-1 and 
GAPDH amplification were designed against the feline sequences. 
With respect to preproET-3 and ECE-1, the primers were designed 
against the rat sequence for these genes, because the feline sequences 
have not been published yet. For every experiment of real-time 
RT-PCR we obtained a melting curve of the amplified gene where it 
could be appreciated that only a specific product was amplified in 
each case with no primer-dimer formation.
Reactive Oxygen Species Measurements
Intracellular reactive oxygen species (ROS) production was measured 
by epifluorescence.14 The myocytes were incubated with 20 ^mol/L 
dichloride-hydrofluorescein diacetate at room temperature for 1 hour. 
After washing with extracellular solution, the myocytes were placed on 
a perfusion chamber of an inverted microscope and excited at 480 nm. 
The emitted light was collected at 530 nm by a photomultiplier 
connected to a digital converter and stored in a computer (Ionoptix 
system). Before obtaining the signal, background fluorescence was 
subtracted.
Immunohistochemistry
Myocyte suspensions were fixed with 4% paraformaldehyde in 
phosphate buffer during 30 minutes and washed in 5% sucrose in 
phosphate-buffered saline (PBS). They were additionally incubated 
for 48 hours with antibodies against preproET (preproET-1, Bachem 
T-4306, rabbit polyclonal against fragment 94-09 or Bachem T-4751, 
rabbit polyclonal against fragment 110-30), BigET-1 (Bachem T-4572, 
rabbit polyclonal), and ET-1 (rabbit polyclonal, Bachem T-4050 or 
mouse monoclonal, clone TR.ET.48.5., Oncogene). Epitopes recog­
nized by the antiserum against preproET-1 are not present in the 
smaller peptides. On the other hand, mature peptides are recognized 
by antibodies directed against their folded tertiary structure, which 
requires cleavage of the precursor molecules. Bound antibodies were 
detected with fluorescein-5-isothiocyanate– conjugated or lissamine 
rhodamine– conjugated anti-rabbit or anti-mouse IgGs (Jackson Im­
munoresearch Laboratories, West Grove, PA). Negative controls 
were made by replacing the primary antibody with its diluent.15
Glycerol mounted specimens were observed with the Laser 
Scanning System Radiance 2000 (BioRad) using the 488 line of the 
argon laser followed by the 543 line of a helium-neon laser and the 
emission filters HQ515/30 and HQ590/70, respectively. Optical 
sections (1 ^m) were performed in the z axis, and images were 
processed using Lasersharp 2000 (BioRad) and Confocal Assistant 
Software (BioRad).
Statistics
Data are expressed as mean^SEM. Paired t test or repeated- 
measures 1-way ANOVA followed by Student–Newman–Keuls as 
post-hoc test were used as appropriate. A P^0.05 was considered to 
indicate significant differences.
Drugs
BQ123 and N-(2-mercapto-propionyl)glycine (MPG) were pur­
chased from Sigma Chemical. TAK044 and HOE642 were kindly 
donated by Takeda Chemical and Aventis Pharma, respectively. 
KB-R7943 and Losartan were purchased from Tocris and Merk, 
Sharp, and Dhome, respectively.
The drugs used in the present study did not significantly affect 
basal contractility, with the exception of KB-R7943, which slightly 
but statistically significantly decreased basal contractility (SL short­
ening relative to initial SL were 5.1^0.4% in control and 4.2^0.5% 
in KB-R7943; P^0.05). Although the nonselective actions of this 
compound were mainly reported to be present at higher doses than 
that used in this study,16,17 we cannot rule out completely an action 
of this compound mediated through mechanisms other than the 
inhibition of the Na^/Ca2^ exchanger (NCX) reverse mode.
Results
Figure 1A and 1B shows the positive inotropic effect (PIE) 
induced by 1 nmol/L Ang II on a continuous recording of a 
myocyte SL. The overall results obtained using 11 myocytes 
are shown in Figure 1C. Ang II induced an increase in SL 
shortening of ^30% over basal levels, a PIE similar to that 
observed previously in cat papillary muscles.18 Figure 1D 
shows the concentration-effect curve of Ang II before and 
after the inhibition of the ET receptors by the nonselective 
blocker (blocks ETA/ETB) TAK044 (1 ^mol/L). These results 
indicate that Ang II induces a concentration-dependent in­
crease in sarcomere shortening, reaching the maximal effect 
at concentrations of 100 nmol/L (^70% increase in basal 
contractility). The PIE induced by 500 nmol/L Ang II was 
lower than that observed with 100 nmol/L. ET receptor 
blockade induces a downward shift in the concentration– 
effect curve. This shift decreased the maximal effect of Ang 
II by ^30% and cancelled the effect of 1 nmol/L Ang II. 
Therefore, these findings demonstrate that the PIE induced by 
1 nmol/L Ang II is entirely attributable to an autocrine 
pathway involving an ET isoform. Concentrations ^1 nmol/L 
are, perhaps, also acting through mechanisms other than the 
autocrine signals triggered by ET and are beyond the scope of 
the present study. Therefore, based on these results, we decided 
Figure 2. The signaling pathway for the positive inotropic effect induced by 1 nmol/L Ang II. The average changes in SL shortening, 
expressed as ^% of the control, with 1 nmol/L Ang II (n^11), and with the same concentration of Ang II but in the presence of 
1 ^mol/L losartan (n ^  5), 1 ^mol/L TAK044 (n ^  11), 10 ^mol/L BQ123 (n ^  6), 10 ^mol/L HOE642 (n ^  6), 1 ^mol/L KB-R7943 (n ^  5), and 
1 mmol/L MPG (n ^  6) are shown. All of the interventions abolished the PIE induced by 1 nmol/L Ang II, indicating that this peptide 
releases/produces endogenous ET after stimulation of the AT1 receptor. Endogenous ET, in an autocrine fashion and through its ETA 
receptor, activates the NHE-1 and the reverse mode of the NCX, leading to an increase in contractility. In addition, the results also sug­
gest the participation of ROS in this positive inotropic effect induced by the interaction between Ang II and ET. *P^0.05 vs control.
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to analyze in detail the PIE induced by 1 nmol/L Ang II, which 
is mediated by the autocrine effect of ET.
Figure 2 shows that the PIE induced by 1 nmol/L Ang II 
was totally prevented by pretreatment of the myocytes with 
losartan (1 ^mol/L) indicating that the release/production of 
ET is entirely attributable to stimulation of the Ang II type 1 
(AT1) receptors. The effect of Ang II was also blunted by 
TAK044 and by the ETA blocker BQ123 (10 ^mol/L; Figure 
2). Therefore, 1 nmol/L of Ang II induces an increase in 
inotropism through release/production of ET after stimulation 
of its AT1 receptor.
We have shown previously that the PIE produced by 1 
nmol/L Ang II in cat papillary muscles was totally prevented by 
the inhibition of the Na^/H^ exchanger (NHE)-1 or of the 
reverse mode of the NCX with the selective blockers HOE642 
and KB-R7943, respectively.18 Results similar to those we 
reported previously in papillary muscles were obtained in the 
isolated myocytes (Figure 2). These results indicate that the 
activation of the NHE-1 and the stimulation of the NCX reverse 
mode are the only mechanisms by which that concentration of 
Ang II increases contractility.
To provide additional evidence that Ang II induces the 
release/production of ET from the myocyte, a number of 
experiments were performed in which isolated cat myocytes 
were exposed to 1 nmol/L Ang II, and preproET-1, preproET-3, 
and ECE-1 mRNAs were measured. After 15 minutes of 
exposure to Ang II, isolated cat ventricular myocytes showed a 
significant increase in the expression of preproET-1 mRNA 
(Figure 3A) but not in preproET-3 or ECE-1 mRNAs (Figure 3B 
and 3C). The Ang II–induced increase in preproET-1 mRNA 
was blocked by losartan (Figure 3A).
The concentrated cardiomyocyte suspension used in RT- 
PCR experiments could possibly be contaminated with non­
myocytes (fibroblasts, endothelial cells, etc), leading to a 
misinterpretation of the above results. Since the presence of 
the synthetic and processing machinery for ET in adult 
cardiomyocytes is controversial,19,20 and species differences 
might exist, we examined the potential presence of 
preproET-1, BigET-1, and ET-1 in cat cardiomyocytes by 
immunohistochemistry. The signal for preproET-1, BigET-1, 
and ET-1 was positive in cardiac myocytes (Figure 4). 
Positive staining was observed in 5 of 5 preparations. Immu­
nostaining of isolated myocytes was obtained with all of the 
tested antibodies. No significant differences were observed 
with monoclonal or polyclonal anti-ET1 antibodies or with 
antibodies against different fragments of preproET-1. Immu­
noreactivity was present in the myocyte cytoplasm and absent 
from myocyte nuclei. The presence of immunoreactivity for 
preproET-1, BigET1, and ET-1 indicates that myocytes con­
tain the synthetic and processing machinery for ET.
Since the generation of ROS by Ang II and/or ET-1 is well 
established,5–11 the effect of the ROS scavenger, MPG 
(1 mmol/L), on the PIE induced by the autocrine pathway of 
Ang II/ET was examined. This compound has been con­
firmed previously as a scavenger of the hydroxyl radical.21,22 
The Ang II–induced PIE was totally prevented by pretreat­
ment of myocytes with MPG (Figure 2).
To determine whether the ROS generated by Ang II results 
in the release/production of ET or whether ROS are acting
Figure 3. Real-time RT-PCR. (A) Significant increase in the 
expression of mRNA of preproET-1 induced by 1 nmol/L Ang II. 
This increase was prevented by losartan. The mRNA levels for 
preproET-3 (B) and ECE-1 (C) did not change with 1 nmol/L 
Ang II. *P^0.05 vs control.
downstream of ET, we examined the effect of the scavenger 
MPG on the PIE induced by exogenous ET-1 applied at a 
concentration (0.4 nmol/L) that resulted equipotent to the 
effect of 1 nmol/L Ang II. The PIE induced by 0.4 nmol/L 
ET-1 was inhibited by MPG (Figure 5), suggesting that the 
ROS are acting downstream to the activation of the ETA 
receptors by ET-1. Therefore, it appears that Ang II–induced 
ET-1 release stimulates an increase in ROS generation, 
which, in turn, triggers the increase in contractility. To 
evaluate this hypothesis, we assessed the role that ET-1 plays 
in ROS generation using epifluorescence techniques. Figure 6 
shows that Ang II increased ROS production and that this 
increase was blunted by the nonselective blockade of ET
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Figure 4. Isolated cat myocytes showing immunofluorescence for endothelin precursors and the mature peptide. (A and B) Immuno­
staining with anti-preproET-1 (fragment 110 to 130), labeled with FITC-conjugated goat anti-rabbit IgG. (C and D) Immunostaining with 
anti-BigET1 labeled with lissamine rhodamine– conjugated goat anti-rabbit IgG. (E and F) Immunostaining with monoclonal anti-ET-1 
antibody labeled with FITC-conjugated goat anti-mouse IgG. Each row shows a negative control (left) and specific immunofluorescence 
(right). Because a single optical section (1 ^m) is illustrated for each experiment, differences in optical density between right and left 
panels indicate the presence of significant amounts of immunoreactive peptides. ET-1 immunofluorescence appears uniformly distrib­
uted within the myocytes, whereas precursors exhibit a patterned distribution suggesting some selective association with the myofibrils 
or sarcomeres. Immunofluorescence density is reduced at the level of cell nuclei (n). Calibration bar for all figures, 25 ^m.
receptors. A representative time course of these experiments 
is shown in Figure 6A. Figure 6B depicts the average increase 
in ROS after 15 minutes of Ang II treatment and the blocking 
effect of MPG, losartan, TAK044, or BQ123 on ROS produc­
tion. The suppression of ROS production is consistent with the 
lack of Ang II–induced PIE in the presence of MPG. The 
possibility that TAK044 was acting as a scavenger was elimi­
nated, because this compound failed to prevent the H2O2 
(5 ^mol/L)-induced increase in contractility (H2O2: 112^9%, 
n^4; H2O2^TAK044: 112^20%, n^4) and in ROS production 
(n^2, data not shown). Finally, we detected that 0.4 nmol/L
Figure 5. Effect of exogenous ET-1 on SL shortening. We exam­
ined the effect of exogenous ET-1 at an equipotent inotropic 
concentration (0.4 nmol/L) to the effect of 1 nmol/L Ang II. The 
PIE induced by ET-1 (n^5) was inhibited by MPG (n^7), indicat­
ing that ROS are targeting ET-1 intracellular signals leading to 
the increase in SL shortening. *P^0.05 vs control.
ET-1 induced a similar increase in ROS production (^ROS with 
respect to the control: 101^36 fluorescence units, n^5) to that 
produced by 1 nmol/L Ang II (Figure 6B). Thus, the data 
indicate that the production of ROS by Ang II is downstream to 
the Ang II–mediated release/production of ET-1.
Discussion
The present study shows that Ang II induces the release/pro- 
duction of ET, which acts in an autocrine fashion to trigger 
ROS production and the intracellular signaling that leads to 
the Ang II–induced PIE. Herein, we detected the presence of 
preproET-1, BigET-1, and ET-1 in cardiomyocytes and found 
that Ang II was able to increase the preproET-1 mRNA level 
in the cardiomyocyte suspension. These results, together with 
the results of contractility and epifluorescence, which were 
performed in isolated myocytes in a flow-superfusing cham­
ber, suggest that the interaction between Ang II and ET-1 
involves an autocrine mechanism. It was reported recently 
that the hypertrophic action of tri-iodothyronine was com­
pletely abolished by cardiomyocyte-specific disruption of the 
ET-1 gene, which supports the autocrine action of this 
peptide.20 However, the potential presence of endothelial 
cells in the cardiomyocyte suspension used in the present 
study does not allow us to unequivocally disregard cells other 
than myocytes as putative sources of this peptide. Therefore, 
although unlikely, the possibility exists that the increase in 
ET-1 mRNA detected in response to Ang II could be 
produced, at least in part, by those nonmyocyte cells.
Although the RT-PCR experiments performed in the pres­
ent work do not elucidate the mechanism by which Ang II 
induces the release/production of ET, they suggest that Ang II
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Figure 6. Ang II–induced ROS production. (A) Representative time course of the increased ROS production by 1 nmol/L Ang II deter­
mined by epifluorescence. This increase was inhibited by TAK044. (B) Average increase in ROS production after 15 minutes of Ang II. 
This increase was prevented by MPG, losartan, TAK044, or BQ123. These data indicate that the production of ROS by the Ang II/ET 
autocrine pathway occurs downstream to the action of endogenous ET acting on its ETA receptors. *P^0.05 vs control.
increases the de novo production of ET-1 in the isolated 
myocytes. It seems unlikely that the increase in preproET-1 
mRNA levels in 15 minutes on Ang II exposure could explain 
the acute PIE induced by this peptide during that time frame, 
because production of mature ET-1 to be released by the 
myocyte would require a greater time period. However, it 
appears valid to assume, if the translation efficiency is not 
altered, that the Ang II–induced release of preformed ET-1 
may be followed by an increase in its mRNA abundance to 
restore the intracellular pools. On the other hand, we were 
unable to detect changes in ECE-1 mRNA after 15 minutes of 
Ang II. This finding in adult cat myocytes is in accordance 
with the report of Xia and Karmazyn23 in cultured neonatal 
rat cardiomyocytes treated with Ang II in which an increase 
in preproET-1 mRNA without any change in ECE mRNA 
was detected.
In the present study, we have shown that TAK044 was able to 
completely block the PIE induced by 1 nmol/L Ang II and to 
partially inhibit the PIE induced by higher concentrations of this 
peptide. Two alternative explanations can be proposed for 
the inability of this blocker to suppress the PIE induced by 
the higher concentrations of Ang II tested: (1) incomplete 
blockade of ET receptors by TAK044, or (2) an inotropic 
effect mediated through a different mechanism than that 
triggered by the autocrine effect of ET-1. The latter 
possibility appears more likely considering that we12,24 and 
others25,26 have reported the stimulation of L-type calcium 
channels by concentrations of Ang II ^1 nmol/L. Neverthe­
less, we would like to emphasize that concentrations of 1 
nmol/L are similar to the physiological concentration range of 
Ang II in the interstitial myocardium27 and are perhaps the 
most relevant concentrations involved in pathophysiological 
actions.
It was reported recently that the production of ROS is not 
involved in the negative inotropic effect of 1 mmol/L Ang II 
observed in rat cardiomyocytes.28 The discrepancy in the oppo­
site inotropic effects and in the involvement of ROS in these 
Ang II–induced effects could be attributed to species differences 
and/or to the significantly higher doses (1000-fold) used in rat 
myocytes.28 Furthermore, it is important to mention that ET 
receptors do not appear to play any role in the contractile effects 
of Ang II on rodent cardiomyocytes.29,30
The experiments in the present study were performed in the 
presence of extracellular HCO3^. Thus, the activation of 
the NHE would lead to an increase in intracellular Na^ in the 
absence of changes in intracellular pH,18,31,32 making it 
unlikely that changes in intracellular pH are the cause of the 
inotropic changes. The reverse mode of the NCX appears to 
be the mechanism playing a pivotal role in the Ang II– 
induced PIE, considering previous data obtained in papillary 
muscles18 and the data presented herein. In addition, the fact 
that the Ang II/ET pathway induced similar inotropic re­
sponses in multicellular preparations and in isolated myo­
cytes and that, in both cases, these responses were prevented 
by NHE or NCX reverse-mode inhibition, enable us to 
suggest that the mechanism involved is of an autocrine 
nature, with the myocyte being the source and target of 
endogenous ET-1.
The finding that Ang II increases ROS production was 
expected according to several reports, which indicate that 
Ang II stimulates NADPH oxidase.5–7 Surprisingly, this 
augmented ROS production induced by Ang II was abolished 
by blocking ETA receptors. Nevertheless, the stimulation of 
NADPH oxidase by ET-1 has been reported previously9,10 in 
addition to the role played by ROS generation after ET-1 in 
determining the increase in contractility in the atria.11 Fur­
thermore, in smooth muscle, vasopressin exerts the increase 
in superoxide levels through the action of endogenous ET-1.33 
It remains currently unknown whether or not every effect of 
Ang II on ROS level is mediated through ET-1. However, 
based on the present findings and those of Ortiz et al,34 it 
appears that at least the effects of subpressor doses of Ang II 
are mediated through ET-1.
The mechanism by which Ang II releases/produces ET was 
not investigated in the present study. A recent study per­
formed in smooth muscle myocytes suggested that Ang II
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induces the synthesis of ET-1 through the production of 
superoxide and the stimulation of extracellular-regulated 
kinase 1/2.8 However, in the present study, ROS production 
and the PIE induced by Ang II were abolished by blocking the 
ET receptors. However, the possibility that a certain amount 
of superoxide not detected in our ROS measurements is 
inducing ET synthesis and that the ET released by this 
mechanism is additionally increasing the production of the 
same or another ROS from the same or another source cannot 
be completely ruled out. In relation to this, Kimura et al7 
suggested recently that low levels of superoxide produced by 
Ang II–induced NADPH oxidase activation might be respon­
sible for triggering the production of a greater level of ROS 
by mitochondria (ROS-induced ROS-release mechanism). 
Moreover, in smooth muscle, it was reported that Ang II 
increases ROS production by the stimulation of the NADPH 
oxidase, whereas ET-1 increases ROS production through 
mitochondrial-derived pathways.35 In summary, although we 
can certainly conclude that the ET released/produced by Ang 
II is promoting the production of ROS, we cannot disregard 
the possibility that, in the Ang II/ET autocrine pathway 
described in the present work, ROS may be involved in 
multiple steps.
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Perspectives
Our results in adult cat ventricular myocytes are, perhaps, 
relevant to the hypertrophic effect of Ang II. In the present 
work, we present evidence that Ang II, through its AT1 
receptors, increased the release/production of ET-1, which 
enhances the activity of the NHE-1 through ROS generation. 
The central role of ET-1 in cardiac hypertrophy is well 
established. Inactivation of the genes for G^11 and G^q, 
which transduce the signal from the ET receptors, produces 
mice resistant to pressure-overload hypertrophy.36 Further­
more, cardiac hypertrophy induced by tri-iodotironine was 
inhibited by selective disruption of the myocytes ET-1 gene, 
suggesting that the mechanism involved the action of 
myocyte-derived ET-1.20 Finally, it is important to note that, 
after myocardial stretch, an activation of the Ang II/ET 
system occurred, leading to an enhanced activity of the 
NHE-1, which increases intracellular Na^ that promotes Ca2^ 
influx through the NCX reverse mode.37 This phenomenon, 
possibly the basis for the Anrep effect, might be one of the 
links between myocardial stretch and hypertrophy.
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